J.P. Marvel Investment Advisors LLC Buys 155 Shares of Eli Lilly and Company (NYSE:LLY)

J.P. Marvel Investment Advisors LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 0.3% during the 3rd quarter, Holdings Channel reports. The firm owned 56,023 shares of the company’s stock after purchasing an additional 155 shares during the quarter. Eli Lilly and Company comprises 8.1% of J.P. Marvel Investment Advisors LLC’s investment portfolio, making the stock its 2nd biggest holding. J.P. Marvel Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $49,633,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its position in shares of Eli Lilly and Company by 19.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after buying an additional 1,620 shares during the last quarter. Quent Capital LLC lifted its stake in shares of Eli Lilly and Company by 5.3% during the 1st quarter. Quent Capital LLC now owns 4,943 shares of the company’s stock worth $3,846,000 after purchasing an additional 249 shares during the period. Empowered Funds LLC boosted its holdings in shares of Eli Lilly and Company by 8.3% during the first quarter. Empowered Funds LLC now owns 32,027 shares of the company’s stock worth $24,916,000 after purchasing an additional 2,452 shares during the last quarter. Guardian Asset Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 2.7% during the first quarter. Guardian Asset Advisors LLC now owns 3,415 shares of the company’s stock worth $2,657,000 after purchasing an additional 91 shares during the last quarter. Finally, Prospera Private Wealth LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at $260,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on LLY shares. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Guggenheim upped their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Bank of America dropped their price objective on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Finally, Citigroup increased their target price on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,008.41.

Eli Lilly and Company Stock Up 2.7 %

NYSE LLY opened at $797.58 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a fifty-two week low of $561.65 and a fifty-two week high of $972.53. The business has a 50 day moving average price of $901.75 and a two-hundred day moving average price of $867.32. The stock has a market cap of $757.16 billion, a PE ratio of 86.22, a P/E/G ratio of 3.05 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter last year, the company posted $0.10 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 20.4% compared to the same quarter last year. As a group, sell-side analysts predict that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.